Sabin is happy to announce the arrival of our 2012 Annual Report, featuring highlights from our three programs – Vaccine Advocacy and Education, The Sabin Product Development Partnership, and the Global Network for Neglected Tropical Diseases.
For many people throughout the world, the bite of a mosquito is nothing more than a common annoyance. But for individuals living in dengue endemic countries such an annoyance can quickly turn into a life threatening condition.

Reposted with permission from the TAMEST blog, which is run by the Academy of Medicine, Engineering & Science of Texas. 

PDPs Applaud Japan’s First Public-Private Partnership to Spearhead Innovation in Global Health

A new public-private partnership of the Japanese Government, the Bill &Melinda Gates Foundation and a group of private pharmaceutical companies seeks to foster and harness Japanese innovation to address diseases that disproportionately affect low- and middle-income countries.
As part of the DVI program, a team has been working to develop and advance a model for the impact of dengue vaccine immunization on infection and disease, one that allows the simulation of a wide range of scenarios, including the impact of vector control.
A debate is emerging about the potential use of genetically modified (GM) mosquitoes to combat dengue in the United States and in other countries around the world. Most recently, news out of Brazil indicated that the country plans to breed GM mosquitoes to stop the spread of dengue.

Pages